-
公开(公告)号：US20190055320A1
公开(公告)日：2019-02-21
申请号：US16113061
申请日：2018-08-27
发明人： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC分类号： C07K16/40 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/00
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US20180164321A1
公开(公告)日：2018-06-14
申请号：US15578874
申请日：2016-06-02
发明人： Xi-Tao WANG , Olufemi A. ADELAKUN , Anne C. LEWIN , Alan J. KORMAN , Mark J. SELBY , Changyu WANG , Haichun HUANG , Karla A. HENNING , Nils LONBERG , Mohan SRINIVASAN , Michelle Minhua HAN , Guodong CHEN , Richard Y. HUANG , Indrani CHAKRABORTY , Susan Chien-Szu WONG , Huiming LI
IPC分类号： G01N33/574 , C07K16/28
摘要： Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
公开(公告)号：US20180127513A1
公开(公告)日：2018-05-10
申请号：US15520638
申请日：2015-11-19
发明人： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC分类号： C07K16/40 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/00
CPC分类号： C07K16/40 , A61K39/39558 , A61K45/06 , A61K47/6871 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/57492 , G01N2333/916
摘要： The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
4.发明申请公开(公告)号：US20230077348A1
公开(公告)日：2023-03-16
申请号：US17734907
申请日：2022-05-02
发明人： Nils LONBERG , Mohan SRINIVASAN
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , A61K45/06 , A61K47/68
摘要： The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention arc also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US20200299400A1
公开(公告)日：2020-09-24
申请号：US16612867
申请日：2018-05-24
发明人： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC分类号： C07K16/28
摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US20200268901A1
公开(公告)日：2020-08-27
申请号：US16849757
申请日：2020-04-15
发明人： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC分类号： A61K47/68 , A61K39/395 , C07K16/00 , C07K16/28 , C07K16/30
摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
7.发明申请公开(公告)号：US20180002432A1
公开(公告)日：2018-01-04
申请号：US15646558
申请日：2017-07-11
发明人： Changyu WANG , Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Mohan SRINIVASAN , Karla HENNING , Michelle Minhua HAN , Guodong CHEN , Richard HUANG , Indrani CHAKRABORTY , Haichun HUANG , Susan WONG , Huiming LI
IPC分类号： C07K16/28 , G01N33/574 , A61K47/68 , G01N33/68 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2878 , A61K39/3955 , A61K47/48569 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/2818 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N33/6863 , G01N33/6872 , G01N2333/70578 , G01N2333/7151
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
8.发明申请公开(公告)号：US20160145342A1
公开(公告)日：2016-05-26
申请号：US14949424
申请日：2015-11-23
发明人： Changyu WANG , Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Mohan SRINIVASAN , Karla HENNING , Michelle Minhua HAN , Guodong CHEN , Richard HUANG , Indrani CHAKRABORTY , Haichun HUANG , Susan WONG , Huiming LI
IPC分类号： C07K16/28 , G01N33/574 , A61K39/395
CPC分类号： C07K16/2878 , A61K39/3955 , A61K47/48569 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K16/2818 , C07K16/2863 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N33/6872 , G01N2333/70578
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
9.发明公开公开(公告)号：US20240158524A1
公开(公告)日：2024-05-16
申请号：US18367252
申请日：2023-09-12
发明人： Changyu WANG , Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Guodong CHEN , Richard HUANG , Indrani CHAKRABORTY , Haichun HUANG , Susan WONG , Huiming LI
IPC分类号： C07K16/28 , A61K39/395 , G01N33/574 , G01N33/68
CPC分类号： C07K16/2878 , A61K39/3955 , C07K16/2818 , C07K16/2863 , G01N33/57492 , G01N33/6863 , G01N33/6872 , A61K2039/505 , C07K2317/56 , C07K2317/73 , G01N2333/70578
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20210324072A1
公开(公告)日：2021-10-21
申请号：US17227642
申请日：2021-04-12
发明人： Mark F. Maurer , Tseng-hui Timothy CHEN , Brigitte DEVAUX , Mohan SRINIVASAN , Susan H. JULIEN , Paul O. SHEPPARD , Daniel F. ARDOUREL , Indrani CHAKRABORTY
摘要： The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.033 秒)
